Poster Discussion (Poster 32): Combined Homologous Recombination Deficiency (HRD) Scores and Response to Neoadjuvant Platinum-Based Chemotherapy in Triple Negative and/or BRCA1/2 Mutation-Associated Breast Cancer. M圜hoice HRD: Predicting Platinum Response There is mounting evidence that m圜hoice HRD can help us do that by predicting a therapeutic response to DNA-damaging agents based on patients' unique tumor biology."īelow are the key m圜hoice HRD presentations being highlighted at #ASCO15. "Anybody who has ever had cancer or treated patients with cancer will understand the enormous benefit of getting the right treatment to the right patient at the right time. "The m圜hoice HRD companion diagnostic test stems from Myriad's pioneering research and is a real step forward in realizing the goal of personalized medicine for patients with ovarian, breast and pancreatic cancers and possibly other solid tumors," said Jerry Lanchbury, Ph.D., chief scientific officer, Myriad. The m圜hoice HRD score is a biomarker that indicates the inability of cancer cells to repair DNA damage and reflects a tumor's sensitivity to DNA-damaging medicines such as PARP (poly-ADP ribose polymerase) inhibitors and platinum-based therapies. Myriad's m圜hoice HRD test is the first and only companion diagnostic to measure three modes of homologous recombination deficiency (HRD) including loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions in cancer cells. (NASDAQ: MYGN) today announced new clinical studies on its m圜hoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill. SALT LAKE CITY, Utah, Myriad Genetics, Inc.